Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025

作者：François Blanquart, Vincent Vieillefond, Benoît Visseaux, Claire Nour Abou Chakra, Marta C. Nunes, Alexandra Jacques, Stéphanie Haïm‐Boukobza, Laurence Josset, Valentin Wehrle, Guillaume Deleglise, Thomas Duret, Marie Anne Rameix-Welti, Bruno Lina, Vincent Enouf, on behalf of the RELAB study group, Antonin Bal · 发表于：Eurosurveillance · 年份：2025 · DOI：10.2807/1560-7917.es.2025.30.7.2500074 · 被引用次数：6 · 研究领域：Influenza Virus Research Studies、Respiratory viral infections research、Bacterial Infections and Vaccines

Influenza circulates at high levels in Europe since November 2024. Using a test-negative study based on data from French community laboratories between October 2024 and February 2025, we estimated vaccine effectiveness (VE) against PCR-detected influenza infection (44,420/15,052; positive/negative individuals). For all age groups, the overall VE was 42% (95% CI: 37-46%), with 26% (95% CI: 18-34%) against influenza A and 75% (95% CI: 66-82%) against influenza B. Among individuals ≥ 65-year-olds VE was 22% (95% CI: 13-30%) and among 0-64-year-olds, 60% (95% CI: 56-65%).